Crizotinib (CRZ), an FDA-approved dual c-MET/ALK inhibitor, induced PUMA and Bim, along with p53 stabilization and DNA damage in p53 wild-type and EpCAM-overexpressing CRC [36,37]. This evidence concerns the gene ALK and colorectal carcinoma.